INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42m ago
HOUSE PTR2m ago
SEC 13F1m ago
ROBINHOOD CHAIN1m ago
Public company

JANXJanux Therapeutics, Inc.

CIK 0001817713

EDGAR filingsOpen in network
Disclosed transactions25
Buys / sells0 / 9
Max Insider Score40
Connections9with evidence

JANX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
28
DN
Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
JANXJanux Therapeutics, Inc.
Open-market sale
SELL$57K
4,059 sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Go WilliamChief Medical Officer · Feb 4, 2026
  • ← Insider ofevidence
    Campbell David AlanDirector, President and CEO · Jan 2, 2026
  • ← Insider ofevidence
    Winter Charles M.Chief Technical Officer · Jan 2, 2026
21
DM
Dobek MariaVice President, Accounting
JANXJanux Therapeutics, Inc.
Open-market sale
SELL
$29K
2,038 sh
May 11, 2026
May 13, 2026
traded May 11, 2026
+2d
SEC FORM 4

Evidence

9
GW
Go WilliamChief Medical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
44.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

9
GW
Go WilliamChief Medical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
154.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

39
CA
Campbell David AlanDirector, President and CEO
JANXJanux Therapeutics, Inc.
Open-market sale
SELL$111K
8,072 sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

9
CA
Campbell David AlanDirector, President and CEO
JANXJanux Therapeutics, Inc.
Grant or award
A—
338.1K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

36
WM
Winter Charles M.Chief Technical Officer
JANXJanux Therapeutics, Inc.
Open-market sale
SELL$33K
2,401 sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

9
MZ
McIver ZachariahChief Medical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
101.5K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

36
DT
DiRaimondo ThomasChief Scientific Officer
JANXJanux Therapeutics, Inc.
Open-market sale
SELL$34K
2,505 sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

32
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Open-market sale
SELL$26K
1,879 sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

17
CA
Campbell David AlanDirector, President and CEO
JANXJanux Therapeutics, Inc.
Grant or award
A—
96.6K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

40
DM
Dobek MariaVice President, Accounting
JANXJanux Therapeutics, Inc.
Open-market sale
SELL$20K
1,462 sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

21
DN
Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
JANXJanux Therapeutics, Inc.
Grant or award
A—
36.0K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

9
DN
Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr
JANXJanux Therapeutics, Inc.
Grant or award
A—
126.0K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

40
MZ
McIver ZachariahChief Medical Officer
JANXJanux Therapeutics, Inc.
Open-market sale
SELL$37K
2,714 sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

21
MZ
McIver ZachariahChief Medical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
29.0K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

21
DM
Dobek MariaVice President, Accounting
JANXJanux Therapeutics, Inc.
Grant or award
A—
18.9K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

9
DM
Dobek MariaVice President, Accounting
JANXJanux Therapeutics, Inc.
Grant or award
A—
42.6K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

17
DT
DiRaimondo ThomasChief Scientific Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
31.4K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

9
DT
DiRaimondo ThomasChief Scientific Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
109.9K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

17
WM
Winter Charles M.Chief Technical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
28.6K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

9
WM
Winter Charles M.Chief Technical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
100.1K sh
Jan 2, 2026Jan 2, 2026
traded Jan 2, 2026
+0dSEC FORM 4

Evidence

0
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$35K
3,333 sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC FORM 4

Evidence

0
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,333 sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC FORM 4

Evidence

8
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$100K
3,333 sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC FORM 4

Evidence

  • ← Insider ofevidence
    McIver ZachariahChief Medical Officer · Jan 2, 2026
  • ← Insider ofevidence
    DiRaimondo ThomasChief Scientific Officer · Jan 2, 2026
  • ← Insider ofevidence
    Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr · Jan 2, 2026
  • ← Insider ofevidence
    Dobek MariaVice President, Accounting · Jan 2, 2026
  • ← Insider ofevidence
    Meyer Andrew HollmanChief Business Officer · Nov 14, 2025